You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer

 

Online download statistics by month:

Online download statistics by month: February 2020 to March 2024

AbstractFullPdf
Feb 202016164
Mar 2020492492190
Apr 202017517577
May 2020787844
Jun 2020696997
Jul 2020646452
Aug 2020494938
Sep 2020636326
Oct 202010710739
Nov 2020666528
Dec 2020737348
Jan 2021989830
Feb 2021818136
Mar 2021878737
Apr 2021484832
May 2021606029
Jun 2021626240
Jul 2021454532
Aug 2021565633
Sep 2021616141
Oct 2021666663
Nov 2021464645
Dec 2021454523
Jan 2022485025
Feb 2022707038
Mar 20229710354
Apr 2022798359
May 2022495035
Jun 2022616835
Jul 2022434727
Aug 2022565859
Sep 2022444947
Oct 2022969654
Nov 2022717352
Dec 2022414117
Jan 2023505230
Feb 202311411542
Mar 2023606146
Apr 2023313124
May 2023565732
Jun 2023384017
Jul 2023525325
Aug 2023414218
Sep 202311511530
Oct 2023555521
Nov 2023515126
Dec 2023545426
Jan 2024565736
Feb 2024444423
Mar 2024585974
Total363736802056